Want to see FR:ALERS full AI Analyst Report?
Top Page
Eurobio-Scientific SA
(ALERS)
Select Model
Select Model
Rating:58Neutral
Price Target:
€26.00
▲(31.31% Upside)
Action:Reiterated
Date:09/18/26
The score is driven primarily by mixed financial performance—stronger solvency and continued positive cash generation, but materially weaker and more volatile profitability and cash conversion. Technicals add modest support as the stock trades above major moving averages, though momentum signals are not uniformly positive. Valuation is the main headwind due to the high P/E and lack of dividend yield support.
Positive Factors
Conservative Leverage
Debt-to-equity of about 0.09 and a sizable equity buffer indicate conservative financing. This reduces balance-sheet strain and preserves flexibility to fund product development, distribution expansion, or working-capital needs through the next several quarters.
Negative Factors
Lower Margin Durability
Net margin of about 2.9% in 2025, versus exceptionally high levels in 2021–2022, shows earnings power has reset lower. Even with gross margin around 40–46%, thinner operating profitability leaves less room to absorb execution pressure or reinvest.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Leverage
Debt-to-equity of about 0.09 and a sizable equity buffer indicate conservative financing. This reduces balance-sheet strain and preserves flexibility to fund product development, distribution expansion, or working-capital needs through the next several quarters.
Read all positive factors
Eurobio-Scientific SA (ALERS) vs. iShares MSCI France ETF (EWQ)
Market Cap
€251.14M
Dividend YieldN/A
Average Volume (3M)4.74K
Price to Earnings (P/E)35.9
Beta (1Y)0.19
Revenue Growth6.30%
EPS Growth201.41%
CountryFR
Employees343
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,248,871
10 Day Avg. Volume12,844
30 Day Avg. Volume4,743
Financial Highlights & Ratios
PEG Ratio2.53
Price to Book (P/B)1.36
Price to Sales (P/S)1.48
P/FCF Ratio39.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Eurobio-Scientific SA Business Overview & Revenue Model
Company Description
Eurobio Scientific S.A. specializes in the conceptualization, development, and distribution of sophisticated diagnostic products. Its key therapeutic and research domains include transplantation, infectious illnesses, life sciences, and oncology. ...
How the Company Makes Money
Eurobio Scientific makes money primarily by selling products and services used by laboratories for clinical testing and life-science research. Key revenue streams include: (1) Sales of in-vitro diagnostic products: revenue from commercializing IVD...
Eurobio-Scientific SA Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
74
Positive
Cash Flow
60
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 169.00M | 154.95M | 130.65M | 152.61M | 184.71M |
| Gross Profit | 68.40M | 71.95M | 57.49M | 65.04M | 97.44M |
| EBITDA | 32.04M | 20.40M | 24.55M | 40.49M | 79.63M |
| Net Income | 4.87M | 4.00M | 4.83M | 24.94M | 60.54M |
Balance Sheet | |||||
| Total Assets | 256.76M | 257.17M | 316.33M | 330.42M | 209.22M |
| Cash, Cash Equivalents and Short-Term Investments | 20.66M | 23.07M | 89.03M | 85.94M | 102.39M |
| Total Debt | 16.02M | 34.05M | 100.66M | 113.60M | 15.68M |
| Total Liabilities | 72.83M | 78.31M | 141.16M | 157.75M | 49.00M |
| Stockholders Equity | 183.92M | 178.85M | 175.17M | 172.34M | 159.91M |
Cash Flow | |||||
| Free Cash Flow | 6.28M | 13.45M | 22.71M | 39.01M | 63.61M |
| Operating Cash Flow | 18.85M | 16.70M | 26.77M | 41.85M | 65.46M |
| Investing Cash Flow | -12.89M | -10.74M | -318.00K | -141.76M | -5.47M |
| Financing Cash Flow | -8.16M | -72.09M | -23.50M | 82.31M | -23.75M |
Eurobio-Scientific SA Technical Analysis
Positive
19.80
Price Trends
21.07
Positive
21.52
Positive
22.47
Positive
Market Momentum
1.25
Negative
76.65
Negative
99.42
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALERS, the sentiment is Positive. The current price of 19.8 is below the 20-day moving average (MA) of 21.51, below the 50-day MA of 21.07, and below the 200-day MA of 22.47, indicating a bullish trend. The MACD of 1.25 indicates Negative momentum. The RSI at 76.65 is Negative, neither overbought nor oversold. The STOCH value of 99.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALERS.
Eurobio-Scientific SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | €251.14M | 35.86 | 3.97% | ― | 6.30% | 201.41% | |
56 Neutral | €36.66M | -0.96 | -96.46% | ― | 0.87% | 46.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | €29.25M | 7.27 | -58.93% | ― | 7.43% | ― | |
46 Neutral | €22.42M | -5.20 | -22.03% | ― | 37.28% | 7.83% | |
42 Neutral | €183.79M | -3.27 | 90.10% | ― | 1.79% | 15.89% |
* Healthcare Sector Average
FR:ALERS
Eurobio-Scientific SA
25.10
-0.20
-0.79%
FR:ALMKT
MAUNA KEA TECHNOLOGIES
0.15
0.06
63.33%
FR:ALNOV
Novacyt
0.51
0.05
11.92%
FR:ALDMS
Diagnostic Medical Systems
0.96
-0.41
-29.67%
FR:ALIKO
Ikonisys SA
1.42
-0.10
-6.58%
FR:ALMDT
Median Technologies
3.77
1.02
37.16%
Eurobio-Scientific SA Corporate Events
EB Development moves toward full takeover and potential delisting of Eurobio Scientific
Sep 16, 2026
EB Development, the majority shareholder of Eurobio Scientific, plans to file a public buyout offer followed by a compulsory buyout at €25.30 per share, matching the price of its 2024 tender bid. The proposed offer implies significant premiu...
Eurobio Scientific lifts H1 revenue as proprietary and international sales drive strategic shift
Jul 28, 2026
Eurobio Scientific reported a 5% rise in first-half 2026 revenue to €84.5 million, with proprietary products growing 10% to €31.3 million and now accounting for 37% of sales, while international revenues reached 47%. Overall growth was...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.